Table 1 Baseline demographic profiles and characteristics related to PegIFN response.

From: HBV-miR-3 is closely related to HBV replication and strongly predictive of HBeAg seroconversion in PegIFN-α treated patients

 

All patients (n = 650)

SR (n = 188)

Non-SR (n = 462)

p value

Age (years)

28.16 ± 0.26

26.65 ± 0.65

28.82 ± 0.32

0.000

Male gender

469

132 (70.2%)

340 (73.60%)

0.370

Body weight

63.77 ± 0.45

61.78 ± 0.80

64.50 ± 0.53

0.005

ALT (IU/mL)

191.96 ± 5.43

209.6 ± 10.03

184.72 ± 6.43

0.037

HBV genotypes

B/ C

242/402

92/95

147/310

0.000

D

6

1

5

HBV-miR-3#

5.77 ± 0.04

5.41 ± 0.09

5.91 ± 0.05

0.000

HBV pgRNA#

6.13 ± 0.07

5.9 ± 0.13

6.2 ± 0.07

0.085

HBV DNA#

7.94 ± 0.03

7.85 ± 0.05

8.0 ± 0.05

0.069

HBsAg#

4.27 ± 0.02

4.16 ± 0.04

4.32 ± 0.03

0.001

HBeAg#

3.02 ± 0.02

2.86 ± 0.04

3.08 ± 0.03

0.000

PegIFN-α 2a/2b

221/429

57/131

164/298

0.207

  1. SR HBeAg seroconversion; Non-SR Non-HBeAg seroconversion.
  2. # The log10 transformation was performed prior to analysis. Biomarker units are measured by log10 copies/mL for HBV-miR-3 and HBV pgRNA, log10 IU/mL for HBV DNA, log10 IU/mL for HBsAg, and log10 COI for HBeAg.